For premenopausal women logging serious mileage, bone stress injuries remain a stubborn clinical challenge — one that standard calcium and vitamin D protocols don't fully solve. This small but carefully designed trial suggests that high-dose collagen peptide supplementation may tip the bone remodeling balance toward formation, offering a potentially meaningful nutritional lever for a population at chronic skeletal risk.
Twenty-two endurance-trained women aged 18–35, running at least 35 miles per week, were randomized in a double-blind, placebo-controlled design to either 20 g/day of collagen peptides or an isocaloric maltodextrin control for four weeks. Assessments were timed to the early follicular phase to minimize hormonal confounding. The intervention group showed a statistically significant increase in P1NP — a direct marker of type I collagen synthesis and bone formation — while the control group showed no change (group × time interaction p = 0.04). Notably, no significant effect was detected for CTX-1, a resorption marker, suggesting the response was formation-driven rather than resorption-suppressive. Significant interactions were also observed for sRANKL and IL-6, pointing to modulation of the osteoimmune axis.
Collagen peptides have gained traction in bone and connective tissue research largely because specific hydrolyzed fractions — particularly those rich in Pro-Hyp and Gly-Pro dipeptides — appear to stimulate osteoblast proliferation and reduce osteoclastogenic signaling through the RANKL/OPG pathway. This trial is one of very few to examine these dynamics specifically in premenopausal endurance athletes, who often exist in a state of subclinical energy deficiency that suppresses bone formation independent of calcium intake. The sRANKL and IL-6 findings are mechanistically intriguing but require cautious interpretation given the 22-person sample and four-week window — far too short to observe structural bone changes. This is an incremental, hypothesis-generating pilot; replication in larger cohorts with longer follow-up and actual bone density endpoints is essential before population-level conclusions can be drawn.
